Research activities of the Department of Dermatology, Zurich University Hospital
Our research activities are primarily focussed on basic, patient-oriented translational, and clinical research in:
- Dermato-oncology, where we focus on the pathogenesis, early diagnosis and molecular targeted treatment of skin cancer, particularly in melanoma, cutaneous lymphoma, and non-melanoma skin cancers.
- Immunodermatology, especially innate immunity and T-cell biology in inflammatory skin diseases, notably psoriasis, neutrophilic dermatoses, cutaneous drug eruptions, and severe allergic adverse drug reactions.
- Allergology, emphasizing on drug and food allergies, and specific immunotherapy.
Dermatologischen Klinik
The Departments Research Groups
Clinical Trials
Highlights
Approx. 50 ongoing clinical trials on new therapeutic approaches in skin disease.
FPFV= First patient first visit
LPLV= Last patient last visit
NOP= Number of patient
| Protocol | Study title | FPFV | LPLV | NoP | PI |
|---|---|---|---|---|---|
| Abbott Humira | Nicht vorhanden | 18/02/2008 | 07/08/2008 | 2 | Prof. R. Trüeb |
| Abbott M10-016 | "A Phase 3, Multi-center, Open-label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects who Completed a Preceding Psoriasis Study With ABT-874" | 13/07/2009 | 11/05/2011 | 6 | Prof. L. French |
| Abbott ABT-874-255 | Nicht vorhanden | 07/07/2008 | 29/12/2008 | 8 | Prof. R. Trüeb |
| Abbott ABT-874-255-2 | Nicht vorhanden | 10/10/2008 | 02/06/2009 | 7 | Prof. R. Trüeb |
| AbbottABT-874-255-3 | Nicht vorhanden | 27/03/2009 | 19/10/2009 | 6 | Prof. R. Trüeb |
| Abbvie H13-147 | "An Observational, Multicenter Disease Registry to Evaluate Clinical Practice Trends and Outcomes in Adult and Adolescent Patients with Hidradenitis Suppurativa – UNITE" | 02/02/2015 | ongoing | 3 | Prof. L. French |
| Actelion AC-085A201 | "A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of two doses of ACT-128800, an oral S1P1 receptor agonist, administered up to twenty-eight weeks in patients with moderate to severe chronic plaque psoriasis" | 02/05/2011 | 29/03/2012 | 4 | Prof. L. French |
| ALIGN | "ALIGN – Multi-country, cross sectionAL study to determine patient specIfic and General beliefs towards medicatioN and their treatment compliance to selected systemic therapies in chronic inflammatory diseases (IMID)" | 19/02/2013 | 20/02/2013 | 10 | Prof. L. French |
| Amgen 20120102 | "A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1" | 15/10/2012 | 25/08/2015 | 4 | Prof. L. French |
| CAIN457A2304E1 | "A multicenter, double-blind and open label, 4 year extension study of subcutaneous secukinumab in prefilled syringes, assessing long-term safety, tolerability and efficacy in subjects with moderate to severe chronic plaque-type psoriasis treated with either a fixed dose regimen or on a retreatment at start of relapse regimen" | 11/03/2013 | ongoing | 3 | Prof. L. French |
| CAIN457A3302_OPTIMISE | "Long term clear skin maintenance treatment optimization in patients with moderate to severe chronic plaque psoriasis: A randomized, multicenter, open-label with blinded-assessment, comparative, 52 week study to evaluate the efficacy, safety and tolerability of secukinumab 300 mg s.c." | 07/01/2016 | ongoing | 4 | Prof. L. French |
| Celgene PSOR009 | "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF APREMILAST (CC-10004) IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS" | 22/11/2011 | 06/11/2012 | 1 | Prof. L. French |
| Centocor-Studie C0743T09 | "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Ustekinumab (CNTO 1275) in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis" | 31/06/2006 | 21/02/2011 | 1 | Prof. L. French |
| Creabilis CT 327 PV 01-09 | "A Randomized, Double-Blind, Placebo Controlled Phase II, Multi-Centre, Study of the Efficacy and Safety of CT 327, a topical cream formulation of Pegylated K252a, when administered twice daily for Eight Weeks to Patients with Mild to Moderate Psoriasis Vulgaris." | 07/07/2010 | 29/12/2010 | 5 | Prof. L. French |
| Eli Lilly RHBS | "Protocol I1F-MC-RHBS(a) A 52-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis" | 10/11/2015 | ongoing | 6 | Prof. L. French |
| Haemopep | Nicht vorhanden | 17/03/2008 | 09/11/2009 | 25 | Prof. R. Trüeb |
| Hidradenitis M11-810 | "A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa" | 18/02/2013 | 21/11/2013 | 6 | Prof. L. French |
| Hidradenitis M12-555 | "A Phase 3 Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa" | 06/11/2013 | 02/06/2016 | 5 | Prof. L. French |
| IBSA | Nicht vorhanden | 24/05/2006 | 25/09/2007 | 19 | Prof. R. Trüeb |
| IMTM-Studie | Nicht vorhanden | 05/02/2009 | 30/06/2011 | 19 | Prof. L. French |
| Novartis CAIN457A2304 | "A randomized, double-blind, multicenter study of subcutaneous secukinumab, assessing Psoriasis Area and Severity Index (PASI) response and maintenance of response in subjects with moderate to severe chronic plaque-type psoriasis on either a fixed dose regimen or on a retreatment at start of relapse regimen Study Comparing secukinumab Use in Long-term Psoriasis maintenance therapy: fixed regimens vs reTreatment Upon start of RElapse (SCULPTURE)" | 14/02/2012 | 18/02/2013 | 2 | Prof. L. French |
| Novartis HS CJM112X2202 | "A randomized, double-blind, placebo controlled, multiple dose study to evaluate the clinical efficacy, safety, tolerability, dose relation, pharmacokinetics and pharmacodynamics of CJM112 in moderate to severe chronic hidradenitis suppurativa patients" | 10/07/2015 | ongoing | 5 | Prof. L. French |
| Pantogar 60+ | Nicht vorhanden | 03/03/2008 | 25/02/2010 | 85 | Prof. R. Trüeb |
| Pyoderma | "A PHASE II MULTI CENTER OPEN LABEL PILOT STUDY TO ASSESS A POTENTIAL EFFECT OF AN ANTI-IL-1-? ANTAGONIST IN THE TREATMENT OF PYODERMA GANGRENOSUM" | 28/04/2011 | 21/10/2014 | 6 | Prof. L. French |
| Remicade (Essex) | Nicht vorhanden | 23/03/2007 | 14/09/2007 | 7 | Prof. R. Trüeb |
| SDNTT | "Long-Term Benefits and Safety of Systemic Psoriasis Therapy: Swiss Registry on the Treatment of Psoriasis with Biologics and Systemic Therapeutics based on PsoBest German Registry and in operational cooperation with CVderm in Hamburg." | 29/11/2011 | ongoing | 195 | Prof. L. French |
| Urticana | "A PHASE II RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED SINGLE CENTER STUDY OF CANAKINUMAB TREATMENT OF ADULT PATIENTS WITH MODERATE TO SEVERE CHRONIC IDIOPATHIC URTICARIA" | 15/08/2012 | 02/12/2013 | 13 | Prof. L. French |
| Wolff | Nicht vorhanden | 10/04/2006 | 07/12/2007 | 28 | Prof. R. Trüeb |
| Wyeth | Nicht vorhanden | 27/01/2006 | 18/01/2007 | 5 | Prof. R. Trüeb |